Search
Imlifidase
go.drugbank.com/drugs/DB15258ApprovedInvestigationalChronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. … [A225836,A225921] Imlifidase is a cysteine protease and eliminates Fc-dependent effector functions such as CDC and ADCC by cleaving the heavy chains of human immunoglobulin G (IgG) antibodies.
Cisatracurium
go.drugbank.com/drugs/DB00565ApprovedInvestigational[A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times its neuromuscular blocking potency. … Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.
Categories: Heterocyclic Compounds, 2-RingSynonyms: (1r,2r,1'r,2'r)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]Idarucizumab
go.drugbank.com/drugs/DB09264ApprovedIdarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its … Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of dabigatran.
Products: PRAXBIND®, PRAXBİND 50 MG/ML ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ, 2 ADETOliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of … [A218041] Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.[L15516]
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 奥赛利定Golodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigationalThis is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. … Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD).
Categories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household settingXanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigationalSchizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine. … [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesBrensocatib
go.drugbank.com/drugs/DB15638Approved[A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation. … Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsSynonyms: (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamideNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalNirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … DeFi trial, where a confirmed objective response rate was observed to be 41% compared to 8% with the placebo.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesClascoterone
go.drugbank.com/drugs/DB12499ApprovedInvestigational[L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766] … Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 InhibitorsTrimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigational[A233215] It is hypothesized that trimetazidine inhibits 3-ketoacyl coenzyme A thiolase, which decreases fatty acid oxidation but not glucose metabolism, preventing the acidic conditions that exacerbate … Trimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride